BIO-key’s Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally; Call Tomorrow at 10am ET
Rhea-AI Summary
BIO-key (Nasdaq: BKYI) reported Q2 2026 revenue of $1.92M, up 13% year over year, driven by a 53% increase in license fees to $1.23M, while hardware revenue fell 19% and services declined 28%.
Gross margin rose to 87% from 73%, lifting gross profit to $1.67M. Operating expenses fell 5% to $2.20M, improving the Q2 net loss by 51% to $(577K). For 1H 2026, revenue grew 23% to $4.07M and net loss narrowed 59% to $(782K). A large, fully-reserved hardware order of about $0.8M was delayed from Q2 and is now expected in 2H 2026.
BIO-key completed a 1-for-10 reverse stock split in Q2 and regained Nasdaq listing compliance in July. As of June 30, 2026, the company had $1.4M in cash, then subsequently raised approximately $2.5M via warrant exercises, increasing cash to over $4.5M and reducing a 2025 note balance by $350K.
Positive
- Q2 2026 revenue up 13% to $1.92M
- License fee revenue up 53% year over year to $1.23M in Q2
- Gross margin improved to 87% from 73% in Q2 2025
- Q2 net loss reduced 51% to $(577K)
- 1H 2026 revenue up 23% to $4.07M
- Warrant exercise financing raised $2.5M, cash now over $4.5M
Negative
- Hardware revenue declined 19% in Q2 2026 to $459.6K
- Services revenue declined 28% in Q2 2026 to $231.0K
- Q2 net loss remains $(577K) despite improvement
- Stockholders’ equity decreased to $4.33M from $5.11M since year-end 2025
- Capital actions included issuance of 699,434 shares and 1,236,668 new warrants
- Outstanding 2025 note still $325K after $350K reduction
News Explained
The completed financing raised
Market Reaction – BKYI
Following this news, BKYI has declined 1.33%, reflecting a mild negative market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.72.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 11 | Warrant inducement | Negative | -6.5% | Discounted warrant exercise generated proceeds while adding warrants and dilution exposure. |
| Aug 10 | Security contract | Positive | +3.5% | Portuguese national security agency selected BIO-key and Visualforma for identity security deployment. |
| Aug 07 | Investor call scheduling | Neutral | +1.3% | Company scheduled Q2 investor call and webcast for August 14. |
| Aug 06 | Saudi partnership | Positive | -1.5% | Maktabi Tech partnership targeted identity security expansion across Saudi Arabia's education sector. |
| Jul 28 | Jordan selection | Positive | -10.5% | Jordan's central bank selected BIO-key for a national biometric authentication initiative. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational announcements produced mixed-to-negative reactions, while the latest financing-related announcement aligned with a negative move.
Key Terms
identity and access management technical
warrant inducement transaction financial
reverse stock split financial
multi-factor authentication technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLMDEL, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its second quarter (Q2’26) and first half (1H’26) results and provided its outlook for the second half of 2026 (2H’26). BIO-key will host an investor call tomorrow at 10:00am ET (details below).
Financial Highlights
- Q2’26 revenues increased
13% to$1.9M - Approximately
$0.8M in fully-reserved hardware revenue with a100% gross profit contribution was anticipated in Q2’26 but was delayed and is now anticipated in 2H’26. - Q2’26 gross margin improved to
87% vs.73% in Q2'25,reflecting the increase in high-margin license fee revenue and an increase in sales of fully-reserved hardware inventory. - Q2’26 net loss trimmed by
51% to$(577 K) vs.$(1.2M ) in Q2’25. - 1H’26 revenues grew
23% and the net loss improved by59% vs. 1H’25. - Earlier this week BIO-key raised approximately
$2.5M from the exercise of outstanding warrants at$4.06 per share. Reflecting net proceeds from this financing, BIO-key’s current cash position has increased to over$4.5M .
Outlook
- BIO-key targets revenue growth and profitability for the 2H’26.
Recent Progress
- Saudi Arabia: BIO-key partnered with Maktabi Tech to advance identity security across Saudi Arabia’s education sector and is working with other local partners on other opportunities within the Kingdom’s government.
- Portugal: Portuguese national security agency selected BIO-key and Visualforma to strengthen identity and access management security. Follows earlier Visualforma collaboration for a nationwide rollout of BIO-key’s IAM and biometric authentication technologies across Portugal’s public-sector ecosystem and a contract to secure digital identities in a major tourist city.
- Jordan: Central Bank of Jordan selected BIO-key for its national biometric authentication initiative to modernize how end clients authenticate across Jordan’s financial sector.
- U.S.: Alabama’s AOD Federal Credit Union deployed BIO-key’s phishing-resistant authentication and biometric security solution. AOD serves over 37,500 members across Northeast Alabama.
- Nasdaq Listing: In Q2 BIO-key completed a 1-for-10 reserve stock split to support its Nasdaq listing and regained compliance with Nasdaq listing rules in July.
BIO-key CEO, Mike DePasquale commented, “While the delay of a large hardware order caused our Q2 results to fall short of our expectations, we were able to deliver solid top and bottom-line improvements in both the quarter and first half, and our building business momentum supports a very positive second half outlook.
“Bottomline –– our focus on opportunities in our Europe, Middle East and Africa – our ‘EMEA’ region, is really starting to bear fruit, with signed contracts, new channel partners and a growing base of new project discussions that support our positive outlook. With the growing incidence of international conflicts, political tension and realigning security interests, customers in these regions are highly motivated to strengthen access protection for their mission critical systems. As a result, our powerful, yet flexible biometrically enhanced authentication solutions resonate strongly with their security needs and budgets. Additionally, customers in the EMEA region are often able move more quickly to an agreement and deploy solutions due to generally more favorable regulatory frameworks across most of this territory.
“Our second half outlook is further supported by anticipated projects with government and banking and financial services customers we have been developing over the last few months and in some cases much longer. Supporting the formation of new customer interest is our ongoing sales and marketing outreach, partner co-marketing activities and most importantly, our expanding base of customer references, case studies and growing deployments with globally respected military, defense and police force customers.
“In addition, we are working to highlight the role our biometric authentication capabilities can play in securing the AI ecosystem. Given recent, high-profile AI control failures, we see substantial potential for biometrics to play a critical role in providing non-repudiable authentication approvals for material AI agent actions. We are working to develop strategic partnerships to support this opportunity, as well as to identify potential acquisitions that would help us to leverage our capabilities in this critical area of AI governance opportunities.
“Earlier this week we moved to enhance our liquidity position and balance sheet through a warrant inducement transaction that raised gross proceeds of
Outlook
“Overall, we are pleased with our progress so far this year and the strength of our current outlook for continued growth in the second half, supported by a solid base of opportunities in our pipeline and the large hardware order we now expect by year-end. Top line growth, combined with ongoing financial discipline, should position us to achieve profitability in the second half. It’s a very exciting time for BIO-key as the decades of work we have put into getting to this point are now being recognized by a growing base of private and public sector customers.”
Financial Review
Total revenues increased
Q2’26 hardware revenues decreased
Q2’26 gross profit increased to
BIO-key’s Q2’26 operating expenses decreased
Reflecting increased revenue and gross profit and reduced operating expenses, BIO-key’s Q2’26 net loss improved to
Also reflecting higher revenue and lower operating costs, 1H’26 net loss improved to
Balance Sheet
BIO-key’s stockholders’ equity was
Over the past two weeks, BIO-key reduced the outstanding balance due on its 2025 note by
| Call/Webcast Detail | |
| Date / Time: | Friday, August 14th at 10 a.m. ET |
| Call Dial In #: | 1-877-418-5460 U.S. or 1-412-717-9594 Int’l |
| Live Webcast / Replay: | Webcast & Replay Link – Available for 3 months |
| Audio Replay: | 1-855-669-9658 U.S. or 1-412-317-0088 Int’l; code 7314992 |
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; the impact of tariffs and other trade barriers which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of non-compliance with Securities and Exchange Commission (“SEC”) and Nasdaq periodic reporting requirements due to late filings; the commercial and reputational risk and impact on the trading and liquidity of our common stock due to the recent suspension of trading of our common stock on the Nasdaq Capital Market or in the event that the trading of our common stock is suspended due to non-compliance with existing and or proposed continued listing standards of the Nasdaq Stock Market; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to continue to maintain effective internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K/A for the year ended December 31, 2025 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
| Engage with BIO-key | |
| Facebook – Corporate: | https://www.facebook.com/BIOkeyInternational/ |
| LinkedIn – Corporate: | https://www.linkedin.com/company/bio-key-international |
| X – Corporate: | @BIOkeyIntl |
| X – Investors: | @BIO_keyIR |
| StockTwits: | BIO_keyIR |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800
| BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenues | |||||||||||||||
| Services | $ | 231,005 | $ | 321,996 | $ | 479,388 | $ | 594,594 | |||||||
| License fees | 1,229,345 | 806,087 | 2,595,238 | 1,904,845 | |||||||||||
| Hardware | 459,641 | 568,824 | 990,898 | 804,627 | |||||||||||
| Total revenues | 1,919,991 | 1,696,907 | 4,065,524 | 3,304,066 | |||||||||||
| Costs and other expenses | |||||||||||||||
| Cost of services | 79,716 | 118,301 | 158,214 | 216,445 | |||||||||||
| Cost of license fees | 74,972 | 86,488 | 148,206 | 159,373 | |||||||||||
| Cost of hardware | 794,313 | 536,806 | 1,117,851 | 645,275 | |||||||||||
| Cost of hardware - reserve | (703,050 | ) | (277,415 | ) | (802,020 | ) | (277,415 | ) | |||||||
| Total costs and other expenses | 245,951 | 464,180 | 622,251 | 743,678 | |||||||||||
| Gross profit | 1,674,040 | 1,232,727 | 3,443,273 | 2,560,388 | |||||||||||
| Operating expenses | |||||||||||||||
| Selling, general and administrative | 1,563,027 | 1,680,550 | 2,873,093 | 3,053,074 | |||||||||||
| Research, development and engineering | 640,418 | 636,027 | 1,257,299 | 1,231,802 | |||||||||||
| Total operating expenses | 2,203,445 | 2,316,577 | 4,130,392 | 4,284,876 | |||||||||||
| Operating loss | (529,405 | ) | (1,083,850 | ) | (687,119 | ) | (1,724,488 | ) | |||||||
| Other income (expense) | |||||||||||||||
| Interest income | 386 | 2,092 | 1,062 | 2,095 | |||||||||||
| Loan fee amortization | (20,833 | ) | (60,000 | ) | (41,666 | ) | (120,000 | ) | |||||||
| Interest expense | (27,000 | ) | (25,638 | ) | (54,166 | ) | (61,548 | ) | |||||||
| Total other income (expense), net | (47,447 | ) | (83,546 | ) | (94,770 | ) | (179,453 | ) | |||||||
| Loss before provision for income tax | (576,852 | ) | (1,167,396 | ) | (781,889 | ) | (1,903,941 | ) | |||||||
| Provision for income taxes | - | - | - | - | |||||||||||
| Net loss | $ | (576,852 | ) | $ | (1,167,396 | ) | $ | (781,889 | ) | $ | (1,903,941 | ) | |||
| Comprehensive loss: | |||||||||||||||
| Net loss | $ | (576,852 | ) | $ | (1,167,396 | ) | $ | (781,889 | ) | $ | (1,903,941 | ) | |||
| Other comprehensive income (loss) – foreign currency translation adjustment | (30,595 | ) | 58,805 | (81,094 | ) | 65,608 | |||||||||
| Comprehensive loss | $ | (607,447 | ) | $ | (1,108,591 | ) | $ | (862,983 | ) | $ | (1,838,333 | ) | |||
| Basic and diluted loss per common share | $ | (0.56 | ) | $ | (2.01 | ) | $ | (0.75 | ) | $ | (3.61 | ) | |||
| Weighted average common shares outstanding: | |||||||||||||||
| Basic and diluted | 1,037,155 | 582,113 | 1,036,938 | 526,711 | |||||||||||
Shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split effective April 30, 2026.
| BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| June 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Cash and cash equivalents | $ | 1,379,300 | $ | 2,694,663 | |||
| Accounts receivable, net | 1,731,509 | 1,220,822 | |||||
| Inventory | 375,740 | 370,879 | |||||
| Prepaid expenses and other | 320,086 | 251,323 | |||||
| Total current assets | 3,806,635 | 4,537,687 | |||||
| Equipment and leasehold improvements, net | 34,804 | 67,751 | |||||
| Capitalized contract costs, net | 266,510 | 311,591 | |||||
| Deposits and other assets | 7,976 | 7,976 | |||||
| Operating lease right-of-use assets | 148,721 | 47,953 | |||||
| Investments | 2,500,000 | 2,500,000 | |||||
| Intangible assets, net | 718,430 | 830,357 | |||||
| Total non-current assets | 3,676,441 | 3,765,628 | |||||
| TOTAL ASSETS | $ | 7,483,076 | $ | 8,303,315 | |||
| LIABILITIES | |||||||
| Accounts payable | $ | 411,203 | $ | 507,357 | |||
| Accrued liabilities | 1,169,747 | 1,333,930 | |||||
| Note payable | 699,769 | 604,102 | |||||
| Government loan – BBVA Bank, current portion | 12,351 | 50,530 | |||||
| Deferred revenue, current | 653,529 | 572,513 | |||||
| Operating lease liabilities, current portion | 66,585 | 27,728 | |||||
| Total current liabilities | 3,013,184 | 3,096,160 | |||||
| Deferred revenue, long term | 35,367 | 62,584 | |||||
| Deferred tax liability | 16,500 | 16,500 | |||||
| Operating lease liabilities, net of current portion | 83,147 | 21,266 | |||||
| Total non-current liabilities | 135,014 | 100,350 | |||||
| TOTAL LIABILITIES | 3,148,198 | 3,196,510 | |||||
| Commitments and Contingencies | |||||||
| STOCKHOLDERS’ EQUITY | |||||||
| Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,087,360 of $.0001 par value at June 30, 2026 and 1,085,360 at December 31, 2025, respectively | 109 | 109 | |||||
| Additional paid-in capital | 141,588,797 | 141,497,741 | |||||
| Accumulated other comprehensive income | (6,291 | ) | 74,803 | ||||
| Accumulated deficit | (137,247,737 | ) | (136,465,848 | ) | |||
| TOTAL STOCKHOLDERS’ EQUITY | 4,334,878 | 5,106,805 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 7,483,076 | $ | 8,303,315 | |||
Shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split effective April 30, 2026.
